In this article
Duke Study: H. pylori and Colorectal Cancer Risk in Diverse Populations
Researchers at the Duke University Cancer Institute have found that H. pylori may lead to an increased risk of colorectal cancer, especially for people with color. People of color are more likely to be diagnosed and die of colorectal cancer.
The researchers further explored the link between H. pylori and colorectal cancer. More than half of the world’s population is infected with Helicobacter pylori, bacteria can cause gastric cancer and gastric ulcers. Researchers at Duke University collected samples from subjects of different races and checked antibody levels before cancer developed. Half of the more than 8,000 study participants continue to develop colorectal cancer. To determine whether the presence of antibodies increased the likelihood of developing colorectal cancer, the researchers compared the frequency of antibodies between cancer and non-cancer subjects. They observed similar rates of past infections in the two groups.
Racial Disparities: High Antibody Levels and VacA Protein Association
As a result, a higher percentage of black and Latino subjects had H. pylori antibodies. This finding is consistent in both cancer and non-cancer tissues. Antibodies specific for Helicobacter pylori proteins are most commonly found in different ethnic groups. Most importantly, a high-level antibody to the H. pylori protein-VacA protein is closely related to the incidence of colorectal cancer in African-American and Asian Americans.
The association between H. pylori and colorectal cancer plays a role in people of color and can significantly affect treatment options, action plans, and public health differences related to cancer. Medical professionals can identify high-risk people with colorectal cancer based on the status of Helicobacter pylori and reduce the incidence of cancer through treatment.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.